Eradicating Suicide at Its Roots: Preclinical Bases and Clinical Evidence of the Efficacy of Ketamine in the Treatment of Suicidal Behaviors

Искоренение суицида в его основе: доклинические предпосылки и клинические данные об эффективности кетамина в лечении суицидального поведения
Marco Di Nicola, Giovanni Martinotti, Massimo Di Giannantonio, Maurizio Pompili, Gianluca Serafini, Michele Fornaro, Domenico De Berardis, Yong‐Ku Kim, Antonio Ventriglio, Laura Orsolini, Carmine Tomasetti, Federica Vellante, Annastasia L.C. Fiengo, Giampaolo Perna, Alessandro Carano, Alessandro Valchera, Marilde Cavuto
2018-09-23

NMDA receptor antagonismketaminemTOR signalingmood disorderssuicidal ideation
Despite the continuous advancement in neurosciences as well as in the knowledge of human behaviors pathophysiology, currently suicide represents a puzzling challenge. The World Health Organization (WHO) has established that one million people die by suicide every year, with the impressive daily rate of a suicide every 40 s. The weightiest concern about suicidal behavior is how difficult it is for healthcare professionals to predict. However, recent evidence in genomic studies has pointed out the essential role that genetics could play in influencing person’s suicide risk. Combining genomic and clinical risk assessment approaches, some studies have identified a number of biomarkers for suicidal ideation, which are involved in neural connectivity, neural activity, mood, as well as in immune and inflammatory response, such as the mammalian target of rapamycin (mTOR) signaling. This interesting discovery provides the neurobiological bases for the use of drugs that impact these specific signaling pathways in the treatment of suicidality, such as ketamine. Ketamine, an N-methyl-d-aspartate glutamate (NMDA) antagonist agent, has recently hit the headlines because of its rapid antidepressant and concurrent anti-suicidal action. Here we review the preclinical and clinical evidence that lay the foundations of the efficacy of ketamine in the treatment of suicidal ideation in mood disorders, thereby also approaching the essential question of the understanding of neurobiological processes of suicide and the potential therapeutics.
1
Genomic and clinical risk-assessment studies identify biomarkers of suicidal ideation involving neural connectivity, neural activity, mood, immune responses, and inflammation.
2
Ketamine, an NMDA receptor antagonist, demonstrates rapid antidepressant and concurrent anti-suicidal effects in mood disorders.
3
Preclinical and clinical evidence supports ketamine’s efficacy for reducing suicidal ideation, while contributing to understanding suicide-related neurobiology.
4
Suicide risk remains difficult to predict, underscoring the potential value of combining genomic biomarkers with clinical assessment.
5
The mTOR signaling pathway is highlighted as a neurobiological mechanism potentially linking biomarkers to suicidal behavior and treatment targets.

Suicidal ideation and behaviors in mood disorders

The preclinical and clinical efficacy of ketamine and its neurobiological mechanisms in reducing suicidality

Publication Details
Publication Date
2018-09-23
Journal
Publisher
ISSN
Cited by
179
Access Type
Author Information
Authors
Marco Di Nicola
Giovanni Martinotti
Massimo Di Giannantonio
Maurizio Pompili
Gianluca Serafini
Michele Fornaro
Domenico De Berardis
Yong‐Ku Kim
Antonio Ventriglio
Laura Orsolini
Carmine Tomasetti
Federica Vellante
Annastasia L.C. Fiengo
Giampaolo Perna
Alessandro Carano
Alessandro Valchera
Marilde Cavuto
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%